Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer

Inclusion Criteria: * Stage IIIb and IV NSCLC, excluded squamous cell NSCLC * Age ≥ 65 years * ECOG 0-2 Exclusion Criteria: * Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component * History of haemoptysis * Evidence of tumour invading major blood vessels on imaging * Radiotherapy within 28 days prior to enrolment * Patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam) * Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed * Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6 months before enrolment), myocardial infarction (≤6 months before enrolment), unstable angina, CHF NYHA Class ≥II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication * Non-healing wound, active peptic ulcer or bone fracture * History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment